Financial Survey: AEterna Zentaris (AEZS) vs. Infinity Pharmaceuticals (INFI)

AEterna Zentaris (NASDAQ: AEZS) and Infinity Pharmaceuticals (NASDAQ:INFI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares AEterna Zentaris and Infinity Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
AEterna Zentaris $910,000.00 37.04 -$24.95 million ($1.81) -1.13
Infinity Pharmaceuticals $18.72 million 6.53 -$30.10 million ($1.15) -2.10

AEterna Zentaris has higher revenue, but lower earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than AEterna Zentaris, indicating that it is currently the more affordable of the two stocks.


This table compares AEterna Zentaris and Infinity Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AEterna Zentaris -2,338.61% -732.74% -96.77%
Infinity Pharmaceuticals N/A -85.61% -59.80%

Institutional & Insider Ownership

3.1% of AEterna Zentaris shares are owned by institutional investors. Comparatively, 67.1% of Infinity Pharmaceuticals shares are owned by institutional investors. 6.8% of Infinity Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AEterna Zentaris and Infinity Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEterna Zentaris 0 0 3 0 3.00
Infinity Pharmaceuticals 0 0 1 0 3.00

AEterna Zentaris presently has a consensus price target of $4.33, suggesting a potential upside of 111.38%. Given AEterna Zentaris’ higher probable upside, equities research analysts clearly believe AEterna Zentaris is more favorable than Infinity Pharmaceuticals.

Risk & Volatility

AEterna Zentaris has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500.


Infinity Pharmaceuticals beats AEterna Zentaris on 8 of the 12 factors compared between the two stocks.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply